Shares of Immunogen (NASDAQ:IMGN) gained 10% in pre-market trading after the company reported Q1 results.
Earnings per share were up 43.33% over the past year to ($0.17), which missed the estimate of ($0.15).
Revenue of $13,287,000 higher by 54.79% from the same period last year, which missed the estimate of $14,940,000.
Immunogen hasn't issued any earnings guidance for the time being.
Immunogen hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 01, 2020
Time: 12:00 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/38zm7g3c
Recent Stock Performance
Company's 52-week high was at $7.07
Company's 52-week low was at $1.76
Price action over last quarter: down 30.78%
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.
See more from Benzinga
- Recap: US Silica Holdings Q1 Earnings
- Olympic Steel: Q1 Earnings Insights
- Morning Market Stats in 5 Minutes
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.